Alto Neuroscience
ANRO
97 hedge funds and large institutions have $436M invested in Alto Neuroscience in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 9 closing their positions.
38,295% more call options, than puts
Call options by funds: $8.06M | Put options by funds: $21K
547% more capital invested
Capital invested by funds: $67.4M → $436M (+$368M)
233% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
26% more funds holding
Funds holding: 77 → 97 (+20)
16.93% more ownership
Funds ownership: 61.89% → 78.82% (+17%)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$23M |
| 2 |
PA
Perceptive Advisors
New York
|
+$20.5M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$19.3M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$13M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$7.96M |
| 2 |
O
OrbiMed
New York
|
-$1.57M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.52M |
| 4 |
AC
Almitas Capital
Santa Monica,
California
|
-$1.47M |
| 5 |
AC
Armistice Capital
New York
|
-$1.26M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
101
Prelude Capital Management
New York
| – | -$45.8K | -11,401 | Closed |
|
102
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$5.83K | -1,450 | Closed |
|
|
ASN
103
Advisory Services Network
Atlanta,
Georgia
| – | -$3.22K | -802 | Closed |
|
|
TWD
104
True Wealth Design
Akron,
Ohio
| – | -$507 | -126 | Closed |
|
105
Osaic Holdings
Scottsdale,
Arizona
| – | -$189 | -47 | Closed |
|
ANRO Hedge Fund Activity: Q4 2025 in Review
97 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q4 2025, worth a combined $436M — up 547% from $67.4M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ANRO positions and 9 closed out — a net gain of 21 holders — while 27 added to existing stakes and 25 trimmed.
The largest buyer was Commodore Capital, opening a new position worth an estimated $23M. The largest seller was Marshall Wace, cutting an estimated $7.96M.
- 97 institutional investors held Alto Neuroscience (ANRO) as of Q4 2025, up from 77 in Q3 2025.
- Funds reported $436M of Alto Neuroscience stock for Q4 2025, up 547% quarter-over-quarter.
- 30 funds opened new Alto Neuroscience positions in Q4 2025 and 9 closed out, a net change of +21 holders.
- The largest Alto Neuroscience buyer in Q4 2025 was Commodore Capital, an estimated $23M added.
- The largest Alto Neuroscience seller in Q4 2025 was Marshall Wace, an estimated $7.96M sold.
Based on aggregated 13F filings for Q4 2025.